What is the SELECT Trial? Understanding Landmark GLP-1 Cardiovascular Research

Understanding the SELECT Trial and Its Impact on Heart Health

The SELECT trial stands as one of the most significant cardiovascular studies in recent medical history. This groundbreaking research demonstrated that semaglutide—a GLP-1 receptor agonist commonly known for treating type 2 diabetes and obesity—can substantially reduce the risk of serious cardiovascular events like heart attacks and strokes.

Published in 2023, the SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) transformed our understanding of GLP-1 medications from simply weight loss tools to potentially life-saving treatments for heart disease.

If you're considering GLP-1 therapy or simply want to understand the science behind these medications, the SELECT trial offers compelling evidence about benefits that extend far beyond the scale.

What Exactly Was the SELECT Trial?

SELECT was a large-scale, randomized, double-blind clinical trial conducted across 41 countries involving over 17,600 participants. The study specifically examined whether semaglutide could reduce cardiovascular events in adults aged 45 and older who had established cardiovascular disease and were overweight or obese—but did not have diabetes.

This distinction matters because previous cardiovascular benefits observed with GLP-1 medications had primarily been seen in people with type 2 diabetes. SELECT asked a different question: Could semaglutide protect the hearts of people with existing cardiovascular disease, regardless of diabetes status?

Participants received either weekly injections of semaglutide 2.4 mg (the same dose used for weight management) or a placebo. Researchers then tracked major cardiovascular events over an average follow-up period of about 40 months.

What Did the SELECT Trial Discover?

The results were remarkable. Participants taking semaglutide experienced a 20% reduction in major adverse cardiovascular events compared to the placebo group. Specifically, the study found significant reductions in:

• Cardiovascular death
• Non-fatal heart attacks
• Non-fatal strokes

This 20% risk reduction occurred alongside an average weight loss of 9.4% of body weight in the semaglutide group, compared to just 0.9% in the placebo group. However, statistical analyses suggested that the cardiovascular benefits couldn't be explained by weight loss alone—indicating that semaglutide may offer direct protective effects on the heart and blood vessels.

These findings were so significant that the FDA expanded the approved uses for semaglutide to include reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight conditions.

Why the SELECT Trial Matters for Patients

Heart disease remains the leading cause of death globally. The SELECT trial demonstrated that a medication many people associate primarily with weight loss may serve as an important tool in preventing heart attacks and strokes.

For the millions of Americans living with both cardiovascular disease and excess weight, this research offers new hope. It suggests that addressing weight with GLP-1 therapy might simultaneously protect against some of the most serious health complications.

The trial also reinforces what healthcare providers already suspected: GLP-1 medications work through multiple mechanisms beyond blood sugar control and appetite suppression. These may include reducing inflammation, improving blood vessel function, and stabilizing arterial plaques.

What This Means for GLP-1 Therapy Going Forward

The SELECT trial has fundamentally changed how physicians and patients think about GLP-1 medications. Rather than viewing semaglutide solely as a diabetes or weight loss medication, healthcare providers now recognize its potential role in comprehensive cardiovascular risk management.

This doesn't mean everyone should take semaglutide for heart protection. The SELECT trial specifically studied people who already had established cardiovascular disease along with overweight or obesity. As with any medication, the decision to use GLP-1 therapy should be individualized based on your specific health profile, risk factors, and goals.

If you're interested in learning more about GLP-1 medications and the research behind them, visit ozarihealth.com/blog for additional evidence-based articles.

Key Takeaways

• The SELECT trial demonstrated that semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 20% in people with established heart disease and overweight or obesity
• This landmark study included over 17,600 participants across 41 countries and followed them for more than three years
• The cardiovascular benefits appear to extend beyond weight loss alone, suggesting semaglutide has direct protective effects on the heart and blood vessels
• Based on SELECT trial results, the FDA expanded semaglutide's approved uses to include cardiovascular risk reduction in appropriate patients

Frequently Asked Questions

Who was included in the SELECT trial?

The SELECT trial enrolled adults aged 45 and older who had established cardiovascular disease (previous heart attack, stroke, or peripheral artery disease) and a body mass index (BMI) of 27 or higher, but who did not have diabetes. This specific population helped researchers understand semaglutide's cardiovascular effects independent of blood sugar control.

Does this mean semaglutide can prevent heart disease in healthy people?

The SELECT trial specifically studied people who already had cardiovascular disease, not healthy individuals looking to prevent a first cardiac event. While the results are encouraging, we cannot assume the same benefits apply to people without existing heart disease. Anyone considering semaglutide for cardiovascular protection should discuss their individual risk profile with their healthcare provider.

Are other GLP-1 medications also protective for the heart?

Several GLP-1 receptor agonists have shown cardiovascular benefits in clinical trials, though the SELECT trial specifically examined semaglutide. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is currently being studied for cardiovascular outcomes. Each medication has its own research profile, so it's important to discuss the specific evidence with your healthcare provider.

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, prescribed by licensed providers and shipped to your door. Learn more at ozarihealth.com.

Reviewed by the Ozari Clinical Content Team (OCCT) — health writers and wellness professionals specializing in GLP-1 therapy and metabolic health. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.